Combination of knockout serum replacement and plasma rich in growth factors does not support in vitro spermatogenesis in mice
Moradian SA., Khaledi S., Amirkhani Z., Movahedin M.
Animal Study, published in Sci Rep (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Sci Rep (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40858886
- PMCID
- PMC12381235
- DOI
- 10.1038/s41598-025-16502-7
Abstract (original English)
Cancer treatments can lead to infertility, particularly in prepubertal boys who cannot preserve sperm before therapy. In vitro spermatogenesis offers a promising strategy for fertility preservation in this population by enabling the development of sperm from immature testicular tissue under controlled conditions. This study investigates the effects of a novel culture medium containing plasma rich in growth factors (PRGF) and knockout serum replacement (KSR) on in vitro spermatogenesis. Testicular tissues from five-day-old male NMRI mice were cultured in either a medium containing 5% KSR + 5% PRGF or a control medium containing 10% KSR for 42 days. Histological analysis revealed significant degeneration of peripheral seminiferous tubules in the 5% KSR + 5% PRGF group compared to the control. Gene expression analysis showed reduced levels of spermatogenesis markers (Plzf, Tekt1, Tnp1) and the proliferation marker Ki67, alongside elevated expression of the pro-apoptotic marker Bax. Immunofluorescence confirmed fewer spermatogonial stem cells (PLZF), spermatocytes (SYCP3), and proliferating cells (Ki67), with complete absence of post-meiotic marker ACRBP in the 5% KSR + 5% PRGF group. Additionally, higher Bax and lower Bcl-2 fluorescence intensities were observed in this group. These findings indicate that a medium supplemented with 5% KSR and 5% PRGF is ineffective for supporting
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.